BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$16.98 (+264.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BIODESIX INC grew revenue 34.5% to $102.94M over the twelve months to Jun 30, 2026. Free cash flow was -$20.24M.
Revenue
$102.94M
+34.5% vs. a year earlier
Operating income
-$20.61M
TTM Q2 2026
Free cash flow
-$20.24M
TTM Q2 2026
EPS, diluted
-$3.17
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $240.93M
- P/E ratio
- –
- Price to sales
- 2.34
- Price to book
- 26.35
- Dividend yield
- –
- Free cash flow yield
- -8.40%
Fundamentals
- Revenue
- $102.94M
- Net income
- -$27.76M
- EPS, diluted
- -$3.17
- Free cash flow
- -$20.24M
- Book value per share
- $0.89
- Diluted shares
- 10M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$102.94M+34.5% YoY
Operating income
-$20.61M
Net income
-$27.76M
EPS, diluted
-$3.17
Free cash flow
-$20.24M
Reported periodTrailing twelve months